Allergy Therapeutics Plc (AGY) – Company Profile and SWOT Analysis

Allergy Therapeutics Plc (AGY) – Company Profile & SWOT Analysis, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.

Key Highlights

Allergy Therapeutics Plc (Allergy Therapeutics) is a speciality pharmaceutical company that develops therapies for allergy treatment and allergy prevention. The company offers aluminium-free allergy vaccines and diagnostics. Allergy Therapeutics product portfolio includes Grass Modified Allergen Tyrosine Adsorbed (MATA), Tree MATA, Ragweed MATA, Bee Venom Subcutaneous Immunotherapy (SCIT), and Wasp venom SCIT, among others. It also offers allergen extracts used for skin prick testing. The company’s diagnostics products comprise Pollen, Moulds, Arthropods, Epithelia and others. It has an operational presence in Germany, Italy, Spain, Austria, Switzerland, the Netherlands and the UK, among others. Allergy Therapeutics is headquartered in Worthing, West Sussex, the UK.

Scope

• Detailed information on Allergy Therapeutics Plc required for business and competitor intelligence needs

• A study of the major internal and external factors affecting Allergy Therapeutics Plc in the form of a SWOT analysis

• An in-depth view of the business model of Allergy Therapeutics Plc including a breakdown and examination of key business segments

• News about Allergy Therapeutics Plc , such as business expansion, restructuring, and contract wins

• Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

• Gain understanding of Allergy Therapeutics Plc and the factors that influence its strategies.

• Track strategic initiatives of the company and latest corporate news and actions.

• Assess Allergy Therapeutics Plc as a prospective partner, vendor or supplier.

• Support sales activities by understanding your customers' businesses better.

• Stay up to date on Allergy Therapeutics Plc s business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

LETI Pharma SLU

HAL Allergy BV

Allergopharma GmbH & Co KG

Stallergenes Greer Ltd

Roxall Medizin GmbH

Biomay AG

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Allergy Therapeutics Plc - Key Facts

Allergy Therapeutics Plc - Key Employees

Allergy Therapeutics Plc - Key Employee Biographies

Allergy Therapeutics Plc - Major Products and Services

Allergy Therapeutics Plc - History

Allergy Therapeutics Plc - Company Statement

Allergy Therapeutics Plc - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 – Company Analysis

Company Overview

Allergy Therapeutics Plc - Business Description

R&D Overview

Allergy Therapeutics Plc - Corporate Strategy

Allergy Therapeutics Plc - SWOT Analysis

SWOT Analysis - Overview

Allergy Therapeutics Plc - Strengths

Allergy Therapeutics Plc - Weaknesses

Allergy Therapeutics Plc - Opportunities

Allergy Therapeutics Plc - Threats

Allergy Therapeutics Plc - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026

Allergy Therapeutics Plc, Recent Deals Summary

Section 5 – Company’s Recent Developments

Jan 30, 2026: Allergy Therapeutics announces the appointment of Helge Weiner-Trapness as Chief Strategy Officer Executive Director and Lawrence Allen Wang as Independent Non-Executive Director

Jan 19, 2026: Allergy Therapeutics : Half Year Trading Update

Dec 11, 2025: Allergy Therapeutics Announces Audited Preliminary Results and Publication of Annual Report for the Year Ended 30 June 2025

Jul 21, 2025: Allergy Therapeutics Announces Trading Update for Year Ended June 30, 2025

Jun 10, 2025: Allergy Therapeutics and EAACI Announce Winner of EAACI Early Career Research Award

Jun 06, 2025: Regulatory Research: New Test Improves Quality Control of Allergy Therapeutics

Mar 31, 2025: Allergy Therapeutics : Interim Results for Six Months Ended 31 Dec 2024

Jan 28, 2025: Allergy Therapeutics : Half Year Trading Update for the Six Months Ended 31 December 2024

Section 6 – Appendix

Methodology

Ratio Definitions

About MarketLine

Contact Us

Disclaimer

List of Tables

List of Tables

Allergy Therapeutics Plc, Key Facts

Allergy Therapeutics Plc, Key Employees

Allergy Therapeutics Plc, Key Employee Biographies

Allergy Therapeutics Plc, Major Products and Services

Allergy Therapeutics Plc, History

Allergy Therapeutics Plc, Subsidiaries

Allergy Therapeutics Plc, Key Competitors

Allergy Therapeutics Plc, Ratios based on current share price

Allergy Therapeutics Plc, Annual Ratios

Allergy Therapeutics Plc, Annual Ratios (Cont…1)

Allergy Therapeutics Plc, Annual Ratios (Cont…2)

Allergy Therapeutics Plc, Interim Ratios

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026

Allergy Therapeutics Plc, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

Allergy Therapeutics Plc, Performance Chart (2021 – 2025)

Allergy Therapeutics Plc, Ratio Charts

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026

    Pricing

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports